Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-3773274

Cytokinetics (NASDAQ:CYTK) announced that REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) has opened to enrollment.

As quoted in the press release:

REDWOOD-HCM is a Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor discovered by company scientists, which Cytokinetics is developing for the potential treatment of hypertrophic cardiomyopathy (HCM).

“Our ability to quickly begin REDWOOD-HCM following the recently announced and encouraging Phase 1 data is a result of the enthusiasm of our clinical trial sites and participating investigators working in partnership with our dedicated team here at our company,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “Our Phase 1 study showed CK-274 achieved the intended pharmacodynamic effect and exposure-response relationship reaching steady state pharmacokinetics levels within 14 days, thereby enabling a dose titration regimen at two-week intervals. REDWOOD-HCM is designed to evaluate translation of a flexible dose optimization schedule with CK-274 to therapeutic window and echocardiographic parameters associated with clinical outcomes in patients with HCM.”

Click here to read the full press release.